TD Cowen lowered the firm’s price target on Aspen Aerogels (ASPN) to $9 from $11 and keeps a Buy rating on the shares. Soft Q1 results and Q2 guidance turn “2025 into a transition year on further EV production weakness,” the analyst tells investors. However, the firm’s one to three year U.S. EV demand view is “still more constructive than consensus” and while it is reducing estimates it still likes the risk/reward post pullback, the analyst added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASPN:
- Aspen Aerogels price target lowered to $10 from $22 at B. Riley
- Aspen Aerogels price target lowered to $8 from $16 at Roth Capital
- Aspen Aerogels Faces Challenges Amid New Contract Win
- Aspen Aerogels Navigates Challenges in Earnings Call
- Aspen Aerogels downgraded to Perform at Oppenheimer on deteriorating demand